Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy

British Journal of Cancer

Volumn 90, Issue 4, 2004, Pages 781-786

  Murphy, P S ^a   Viviers, L ^a   Abson, C ^a   Rowland, I J ^a   Brada, M ^a   Leach, H O ^a   Dzik Jurasz, Ask ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Low grade glioma; Magnetic resonance spectroscopy; Temozolomide; Treatment response

Indexed keywords

CHOLINE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; WATER;

ADULT; ARTICLE; CANCER GRADING; CLINICAL ARTICLE; DRUG MONITORING; EVALUATION; GLIOMA; HUMAN; METABOLITE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; TREATMENT OUTCOME; TUMOR VOLUME; BRAIN TUMOR; CLINICAL TRIAL; FEMALE; MALE; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHOLINE; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; TREATMENT OUTCOME; WATER;

EID: 1642275594     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601593     Document Type: Article

References (23)

1. Barba I, Cabanas ME, Arus C (1999) The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res 59: 1861-1868
2. Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361: 323-331
3. Brada M, Hoang-Xuan K, Rampling R, Dietrich PY, Dirix LY, Macdonald D, Heimans JJ, Zonnenberg BA, Bravo-Marques JM, Henriksson R, Stupp R, Yue N, Bruner J, Dugan M, Rao S, Zaknoen S (2001) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12: 259-266
4. Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81: 1022-1030
5. Brada M, Viviers L, Abson C, Hines F, Britton J, Ashley S, Sardell S, Traish D, Gonsalves A, Wilkins P, Westbury C (2003) Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14: 1715-1721
6. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold Jr C et al. (1994) Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12: 2013-2021
7. Glass J, Hochberg FH, Gruber ML, Louis DN, Smith D, Rattner B (1992) The treatment of oligodendrogliomas and mixed oligodendroglioma-astrocytomas with PCV chemotherapy. J Neurosurg 76: 741-745
8. Mason WP, Krol GS, DeAngelis LM (1996) Low-grade oligodendroglioma responds to chemotherapy. Neurology 46: 203-207
9. Miller BL, Chang L, Booth R, Ernst T, Cornford M, Nikas D, McBride D, Jenden DJ (1996) In vivo 1H MRS choline: correlation with in vitro chemistry/histology. Life Sci 58: 1929-1935
10. Nadler JV, Cooper JR (1972) N-acetyl-L-aspartic acid content of human neural tumours and bovine peripheral nervous tissues. J Neurochem 19: 313-319
11. Nelson SJ, Vigneron DB, Dillon WP (1999) Serial evaluation of patients with brain tumors using volume MRI and 3D 1H MRSI. NMR Biomed 12: 123-138
12. Peterson K, Paleologos N, Forsyth P, Macdonald DR, Cairncross JG (1996) Salvage chemotherapy for oligodendroglioma. J Neurosurg 85: 597-601
13. Poptani H, Kaartinen J, Gupta RK, Niemitz M, Hiltunen Y, Kauppinen RA (1999) Diagnostic assessment of brain tumours and non-neoplastic brain disorders in vivo using proton nuclear magnetic resonance spectroscopy and artificial neural networks. J Cancer Res Clin Oncol 125: 343-349
14. Preul MC, Caramanos Z, Villemure JG, Shenouda G, LeBlanc R, Langleben A, Arnold DL (2000) Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 46: 306-318
15. Rajan B, Ross G, Lim CC, Ashley S, Goode D, Traish D, Brada M (1994) Survival in patients with recurrent glioma as a measure of treatment efficacy: prognostic factors following nitrosourea chemotherapy. Eur J Cancer 30A: 1809-1815
16. Rees JH (2002) Low-grade gliomas in adults. Curr Opin Neurol 15: 657-661
17. Ricci PE, Dungan DH (2001) Imaging of low-and intermediate-grade gliomas. Semin Radiat Oncol 11: 103-112
18. Smith ICP, Stewart LC (2002) Magnetic resonance spectroscopy in medicine: clinical impact. Prog Nucl Magn Reson Spectrosc 40: 1-34
19. Stieber VW (2001) Low-grade gliomas. Curr Treat Options Oncol 2: 495-506
20. Tedeschi G, Lundbom N, Raman R, Bonavita S, Duyn JH, Alger JR, Di Chiro G (1997) Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 87: 516-524
21. van den Boogaart A, van Ormondt D, Pijnappel WW, de Beer R, Korpela A (1994) In Mathematics in Signal Processing III, McWhirter JG (ed) Oxford: Clarendon Press
22. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA (2000) A phase II study of temozolomide vs procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83: 588-593
23. Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17: 2762-2771